News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

November 5, 2019 Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results
October 11, 2019 Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019
September 27, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 26, 2019 Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
September 18, 2019 Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration
September 16, 2019 Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes
September 12, 2019 Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes
September 11, 2019 Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes
September 9, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 3, 2019 Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria